Arman Shaz

Peptides & Telehealth for 4 Years. Building The Infrastructure from manufacturing To Distribution

[Arman Shaz @armanshaz_]

I only worked with Peptide companies doing $1M - $10M+ A Month, here’s how I scaled them

No I don’t run your meta ads lol, thats ez

I handle the grunt work backend infrastructure behind some of the biggest companies you’ve definitely heard of

Here’s what I offer 👇

I control a Dallas 50 State Compound Pharmacy (Telehealth) peptide sourcing

50 State Doctor Network (have docs prescribe peptides across 50 states)

Custom packaging: boxes, labels etc…

Fast Legit Script (we’re a LS Enterprise partner)

Peptide Sourcing (RUO Vetted Labs (The lab that peptide sciences used till they shutdown) + other big players

Dallas Peptide 3PL (cooled storage) + Labelling + Lab Testing

Software with API docs that all this plugs into

Compliance + cc processing + Meta Whitelist Ad Accounts (never get shutdown by Zuck again)

Taking on a few companies looking to Blitz Scale, reply with why I should work with you

[Arman Shaz @armanshaz_]

Hiring Sales reps OTE: $20k - $30k+ with growth structure leading to phantom equity if MOM Growth % Attributes according to KPI’s

#peptides #telehealth #sales #highticket #hts #closer

[Arman Shaz @armanshaz_]

@elonmusk They got to him 🤦‍♂️

If anyone has gotten a glimpse of how elons brain works is that he’s hyper fixated and obsessed with what he’s currently building, clearly Israel has setup an incentive for elons projects to get executed much smoother, or got equity in Gaza

[Arman Shaz @armanshaz_]

@DrJesseMorse That’s cap, I’ve toured green-listed API manufacturing labs in china, there’s no way (for now) API is being made from labs here in the US at a comparable scale or at all tbh, would ask them for clear proof or ask for a tour

[Shaun Eng @shauneng]

The supplement niche is gonna get brutal by 2027
⠀
A lot of these categories are just going to die off.

Weight loss already did, GLP-1 came in and wiped the whole thing out.

And it's not like those supplements got out-marketed.

They lost because the drug actually works. And no supplement was ever going to compete with that.

More pharma is coming for more categories too, so the obvious move is to just sell stuff that actually works.
⠀
But that's where it gets tricky, because now you're selling the exact same thing as everyone else.

TRT is TRT. GLP-1 is GLP-1.

There's no version of it that's uniquely yours, and even if you do stumble on some new mechanism, it's copied by next week.

So most of you try to stand out by going "well mine's higher quality" or "my compound's purer." And nobody cares.

Because marketing was never really about the product, it's about what people already believe in their head before they even look at you.

Think about it. The second you tell someone you're better, they get defensive and start hunting for reasons you're not.

But tell them you're different, and now they're curious. They want to know why. And that little bit of curiosity is what makes them decide you're better on their own.

You never had to say it, they got there themselves.
⠀
And it's only getting harder, because you can literally have AI design a world-class formula now, send it off to a contract manufacturer, and have a top-tier product made.

Everyone knows you need an amazing product.

Now anyone can do that. So the product stopped being the edge a while ago. The positioning is.
⠀
So start with one question: what position do you actually own?

Most of you can't even answer that, which is kind of the whole problem.

Look at what your competitors already own in people's heads, then find the gap they've left wide open. That's your white space.

Most ecom bros think they're being smart researching the market and testing whatever they see working, but everything they can see is already taken by someone else.

They're fighting over ground that's owned.
⠀
The move is to figure out what you're against. Because once you know what you're against, what you're for becomes obvious.

Old Spice never changed the actual body wash. They just realised women were the ones buying it for their men, and built the whole brand around that one thing. "The man your man could smell like." Number one men's body wash within a year.
⠀
Black Rifle sells the same coffee as everyone else. They just planted themselves against every faceless brand that stood for nothing. Made by veterans, for veterans. Billion dollar brand.
⠀
Different beats better.
⠀
And the biggest white space is usually just a group of customers nobody's bothering to talk to. Nobody advertises to them because nobody thought to look.
⠀
There's a guy in Evolve who had a hair supplement brand stuck at $2k/day. Same formula as every other brand in the niche, nothing special about it.

But he actually dug into his data, found an older avatar nobody else was going after, and made ads that spoke straight to them. No other brand was even bothering to advertise to these people.
⠀
He Chad scaled it to $55k/day.
⠀
Now, world-class products are basically a commodity, and you're up against these big VC-backed celebrity supplement brands.

So on the surface, yeah, it feels like supplements are way too saturated to get into.
⠀
But we're still going to keep seeing bootstrapped supp brands scale to crazy numbers.

The more brands there are, the more each one has to alienate somebody to carve out its own space.

And that's exactly where you come in.
⠀
That's the part most of you miss.

The brands that win don’t have to be the ones with the best formula. They're the ones nobody else can claim to be.

Few.

[Zim Olson @ZimOlson]

Poets: Opportunities for Math Poetry ideas available at Zim Mathematics . Systems concepts provide innumerable creative Math Poetry ideas. Systems Poetry, Systems Metaphors innumerable.

Scientist, Physicists and even Mathematicians are also welcome !

[Daniel Kornum @dkfromdk]

https://t.co/biv19e804C

[Alex Hormozi @AlexHormozi]

You can boil success into:
Focus + Patience

And they’re so hard because they’re so anti human.

We want new stuff—>unfocused
We want stuff now—>impatient

People fail from poor self control more than poor work ethic or intellect.

You’re not too dumb, you’re too undisciplined.

[Arman Shaz @armanshaz_]

@rahulmodifit Every 6 months or so, gonna go in the winter

[Arman Shaz @armanshaz_]

@rahulmodifit Shenzen, I also have a lab here in Dallas too

[Arman Shaz @armanshaz_]

@Krysia830073 Check my page, visited one of the greenlisted API manufacturers in Shenzen

[Arman Shaz @armanshaz_]

Welcome to Shenzhen China, I’m in one of the biggest green-listed API manufacturing facilities where all peptide raw materials are synthesized, yes even the ones that claim U.S made, this is the storage area: - 20 Degrees 🥶

Raw materials are ready to be shipped to manufacturing facilities in the US where they fill + finish and bottle up your peptides

[Arman Shaz @armanshaz_]

$10,000,00+ of peptides in this room | This batch of peptides might have been in your last jab 👀

[Arman Shaz @armanshaz_]

@calebcanales_ 2 weeks max, I have 42 licenses

[Navalism @NavalismHQ]

Learn to sell. Learn to build. If you can do both, you will be unstoppable.

@naval

[Karthik @kartikktwt]

Be a Delusional Optimist.....

[Paul Graham @paulg]

It seems a mistake to call oneself a "non-technical founder." You're treating not knowing how to do something as a part of your identity. Surely it's better just to fix that.

[DNI Tulsi Gabbard @DNIGabbard]

Today, I’m releasing never before seen intelligence revealing new evidence of past US government funding for more than 120 biolabs in over 30 countries, including Ukraine.

In support of President Trump‘s Executive Order to end federal funding of dangerous gain of function research around the world, and increase transparency and accountability, ODNI will continue working with partners across the Administration to identify where these labs are, what pathogens they contain, and what “research” is being conducted.

https://t.co/pLMD0krc69

[Derek Thompson @DKThomp]

This has quietly been a miracle month in medicine.

In the last 5 weeks we’ve got news on:

- retatrutide, the triple agonist GLP-1 from Lilly, basically melting fat and body-wide inflammation at record levels
- RevMed’s new pancreatic cancer drug showing unprecedented abilities to extend life
- small trial of a one-and-done PCSK9 gene editing therapy for slashing LDL cholesterol
- Mayo’s AI-assisted radiology showing vastly improved cancer detection
- this new therapy for metastatic solid tumors

This stuff is at varying levels of evidence. Retatrutide is ~100% on its way, other stuff needs more clinical trial data. But put it together and we’re maybe on the verge of majorly reducing the mortality of heart disease and cancer, the two leading causes of death in America.